Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
March 30, 2020 at 08:46 pm IST
Share
Evolutionary Genomics, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 774,825 compared to USD 836,799 a year ago. Net loss was USD 793,140 compared to USD 1.098 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.23 a year ago.
Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially traits in crops for the agriculture industry. It uses the Adapted Traits Platform (ATP) to identify commercially valuable genes that control important traits in animals and plants. Its platform identifies genes that have changed successfully to impart new or improved traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes, and cotton. The Company uses ATP to perform throughput molecular evolution analysis to identify positively selected genes based on non-synonymous site (Ka) and synonymous site (Ks) analysis.
EVOLUTIONARY GENOMICS, INC. 
